Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 16.84

From 52W high−46.05%

Volume4.08M

Market capCNY 3.99B

P/E (TTM)24.2x

P/S (TTM)2.5x

Div yield3.29%

Key dataSep 18, 2026

Open

CNY 16.84

From 52W high

−46.05%

Volume

4.08M

Market cap

CNY 3.99B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

14.1x

P/E (TTM)

24.2x

RSI (14)

44.3

MomentumView details →

1D Return

−3.64%

YTD Return

−34.23%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

24.2x

EV/EBITDA

14.1x

EV/Sales

2.5x

P/S (TTM)

2.5x

P/B (TTM)

2.2x

ProfitabilityView details →

Gross Margin

65.18%

Net Margin

10.46%

EBITDA Margin

17.38%

ROE (TTM)

8.80%

ROA (TTM)

6.12%

Asset Turnover

0.59x

GrowthView details →

Revenue YoY

+0.36%

EPS YoY

−2.77%

FCF YoY

+64.51%

Revenue CAGR 3Y

−15.54%

EPS CAGR 3Y

−13.19%

EBITDA YoY

—

MomentumView details →

1D Return

−3.64%

YTD Return

−34.23%

1Y Return

−40.15%

RSI (14)

44.3

vs 50D SMA

−4.68%

vs 200D SMA

−22.45%

Capital & dividendView details →

Debt/Equity

0.04x

Current Ratio

2.28x

Quick Ratio

1.86x

Div Yield

3.29%

Div Rate

CNY 0.56

Div Growth 1Y

+40.00%

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

1.55B

Net Income (TTM)

162.24M

Op. CF (TTM)

240.49M

Latest newsMore news →

Hefei Lifeon Pharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application for celecoxib and tramadol hydrochloride tablets (acceptance number CYHL2600101).2d ago

Lifang Pharmaceutical announced that its doxazosin mesylate extended-release tablets and azilsartan medoxomil potassium tablets are proposed to be selected in the 12th batch of China's national centralized drug procurement, with the procurement cycle lasting until December 31, 2029.49d ago

Similar companies

华帝股份002035.SZ 福恩股份001312.SZ 森鹰窗业301227.SZ 金河生物002688.SZ 天邑股份300504.SZ 华茂股份000850.SZ Find similar companies →

Latest newsMore news →

Hefei Lifeon Pharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application for celecoxib and tramadol hydrochloride tablets (acceptance number CYHL2600101).2d ago Lifang Pharmaceutical announced that its doxazosin mesylate extended-release tablets and azilsartan medoxomil potassium tablets are proposed to be selected in the 12th batch of China's national centralized drug procurement, with the procurement cycle lasting until December 31, 2029.49d ago